Orchestra BioMed Holdings, Inc. OBIO
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 9.98% | -22.68% | -10.32% | 138.66% | -35.02% |
| Total Depreciation and Amortization | 24.69% | 18.52% | 8.43% | -2.38% | 6.58% |
| Total Amortization of Deferred Charges | 10.17% | 41.30% | 39.13% | 106.45% | -- |
| Total Other Non-Cash Items | -144.18% | 23.87% | -32.27% | -6.34% | 57.14% |
| Change in Net Operating Assets | -75.01% | -68.99% | -270.00% | -801.03% | 497.65% |
| Cash from Operations | -34.28% | -24.51% | -33.41% | 83.23% | -6.20% |
| Capital Expenditure | -28.39% | -647.06% | -64.29% | 68.87% | -355.88% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 155.82% | -240.67% | -19.90% | -480.59% | -6,223.84% |
| Cash from Investing | 154.34% | -242.51% | -20.62% | -371.94% | -7,027.11% |
| Total Debt Issued | -100.00% | -- | -- | -100.00% | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -89.57% | -- | 6,362.64% | 2,925.49% | 284.30% |
| Repurchase of Common Stock | 39.78% | 38.79% | 8.53% | 14.91% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -75.45% | -- |
| Cash from Financing | -92.33% | 8,218.22% | 1,967.23% | -9.23% | 408.13% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -68.67% | -2,068.83% | -61.59% | -118.96% | 1,129.55% |